Nanobiotix presents initial data from JNJ-1900 clinical trial
Biotechnology company Nanobiotix presented first data from its randomized Phase 2 clinical trial of JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. The study evaluated the efficacy and safety of hafnium oxide nanoparticles in patients with inoperable stage 3 lung cancer, in combination with standard therapy.
PARIS and CAMBRIDGE, MA – March 30, 2026 – Nanobiotix, a biotechnology company focused on cancer therapies, has presented the first data from the CONVERGE study, a randomized Phase 2 clinical trial of its nanotherapeutic JNJ-1900 (NBTXR3) for patients with inoperable stage 3 non-small cell lung cancer, sponsored by Johnson & Johnson. The findings were presented at the 2026 European Lung Cancer Conference.
Initial results from the study involving seven patients indicated promising treatment responses prior to immunotherapy. The objective response rate (ORR) was 71.4%, and the disease control rate (DCR) was 100% in patients receiving the combination therapy, which included JNJ-1900 (NBTXR3) alongside chemoradiotherapy. An acceptable safety profile was observed, with no serious treatment-emergent adverse events, and the treatment did not hinder patients' ability to continue their planned therapy.
JNJ-1900 (NBTXR3) is composed of functionalized hafnium oxide nanoparticles. It is administered as a single intratumoral injection and activated by radiotherapy. Nanobiotix states its mechanism of action is designed to significantly induce cancer cell death upon activation. The company believes the therapy has the potential to be scaled across any solid tumor treatable by radiotherapy, particularly when combined with immune checkpoint inhibitors.
Nanobiotix continues to actively develop NBTXR3 across other cancer indications, including the global Phase 3 NANORAY-312 study for locally advanced head and neck squamous cell carcinoma. The company is collaborating with multiple research institutions and pharmaceutical companies to broaden the development of this nanotherapeutic candidate for various tumor types and combination treatments.